{"disease":{"id":"waldenstr-m-s-macroglobulinemia-wm","name":"waldenstr m s macroglobulinemia wm"},"drugs":{"marketed":[{"drug_id":"zanubrutinib","indication_name":"Waldenström's macroglobulinemia (WM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06942507","title":"Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03332173","title":"Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"BeiGene","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}